Table 4 Reasons for randomised patients stopping study simvastatin/placebo tablets
Reason(s) given | Simvastatin-allocated (n = 10269) | Placebo-allocated (n = 10267) | Â | ||
|---|---|---|---|---|---|
Patient wishes | 2186 | (21.3%) | 2113 | (20.6%) | Â |
Unable or unwilling to attend clinic | 757 | (7.4%) | 745 | (7.3%) | Â |
Non-study statin started | 364 | (3.5%) | 1401 | (13.6%) | Â |
Other contraindicated drug started | 11 | (0.1%) | 50 | (0.5%) | Â |
Poor compliance | 88 | (0.9%) | 120 | (1.2%) | Â |
Raised liver or muscle enzymes** | 57 | (0.6%) | 46 | (0.4%) | Â |
   Raised liver enzymes | 46 | (0.4%) | 36 | (0.4%) |  |
   Raised muscle enzymes | 11 | (0.1%) | 2 | (0.0%) |  |
Muscle pain or weakness | 60 | (0.6%) | 62 | (0.6%) | Â |
Medical advice | 158 | (1.5%) | 206 | (2.0%) | Â |
Medical diagnosis/treatment/investigation | 143 | (1.4%) | 160 | (1.6%) | Â |
Non-specific adverse events | 110 | (1.1%) | 126 | (1.2%) | Â |
Other adverse events | 229 | (2.2%) | 225 | (2.2%) | Â |
   Gastrointestinal | 114 | (1.1%) | 104 | (1.0%) |  |
   Psychological/psychiatric | 49 | (0.5%) | 54 | (0.5%) |  |
   Rash or skin | 22 | (0.2%) | 22 | (0.2%) |  |
   Neurological | 10 | (0.1%) | 14 | (0.1%) |  |
   Other | 44 | (0.4%) | 43 | (0.4%) |  |
Other or family reasons | 149 | (1.5%) | 141 | (1.4%) | Â |
Any of the above* | 3440 | (33.5%) | 4424 | (43.1%) | P = 0.0000 |